Literature DB >> 18628410

Use of common medications and breast cancer risk.

Kirsten B Moysich1, Gregory P Beehler, Gary Zirpoli, Ji-Yeob Choi, Julie A Baker.   

Abstract

Prescription and over-the-counter medications are widely used in the United States and many western countries. More than two-thirds of women ages >45 years, who are at greatest risk for breast cancer, take prescription medication. In light of the ubiquitous nature of medication use and the fact that breast cancer remains the most common cancer in women, research on the role of medication use in breast cancer etiology is warranted. We summarize the epidemiologic evidence on the association between breast cancer risk and use of common medications, including antibiotics, antidepressants, statins, antihypertensives, and nonsteroidal anti-inflammatory drugs. Overall, there is little evidence that would implicate the use of antibiotics, antidepressants, statins, and antihypertensives in the etiology of breast cancer. Although several prospective studies and a randomized low-dose aspirin chemoprevention trial have not shown lower risk of breast cancer among aspirin users, most studies that have examined the potential chemoprotective effect of nonsteroidal anti-inflammatory drugs have shown significant risk reductions for regular and prolonged use of these drugs. The existing literature on the role of medication use in breast carcinogenesis is complicated. Interpretation of the evidence is hampered due to major methodologic differences across studies, including exposure assessment, exposure classification, and adjustment for potential confounding variables. These differences largely stem from the fact that the majority of articles on this topic represent secondary data analyses from studies with inadequate information on exposure or confounders. Thus, future epidemiologic studies specifically designed to study these ubiquitous and biologically plausible exposures are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628410     DOI: 10.1158/1055-9965.EPI-07-2828

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  11 in total

1.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Authors:  Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

Review 2.  The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives.

Authors:  Demetrios Moris; Michalis Kontos; Eleftherios Spartalis; Ian S Fentiman
Journal:  Breast Care (Basel)       Date:  2016-10-24       Impact factor: 2.860

Review 3.  The role of aspirin in cancer prevention.

Authors:  Michael J Thun; Eric J Jacobs; Carlo Patrono
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

4.  Analgesic use and sex steroid hormone concentrations in postmenopausal women.

Authors:  Margaret A Gates; Shelley S Tworoger; A Heather Eliassen; Stacey A Missmer; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

5.  Cardiometabolic factors and breast cancer risk in U.S. black women.

Authors:  Jaclyn L F Bosco; Julie R Palmer; Deborah A Boggs; Elizabeth E Hatch; Lynn Rosenberg
Journal:  Breast Cancer Res Treat       Date:  2012-06-19       Impact factor: 4.872

6.  Antitumor activity of the Ailanthus altissima bark phytochemical ailanthone against breast cancer MCF-7 cells.

Authors:  Ruxing Wang; Yanjie Lu; Hong Li; Lixin Sun; Ning Yang; Mingzhen Zhao; Manli Zhang; Qingwen Shi
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

7.  Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Authors:  Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen
Journal:  Breast Cancer Res       Date:  2010-03-01       Impact factor: 6.466

8.  Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.

Authors:  Thomas P Ahern; Rulla M Tamimi; Bernard A Rosner; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2014-02-28       Impact factor: 4.872

9.  Analgesic use in relation to sex hormone and prolactin concentrations in premenopausal women.

Authors:  Scott R Bauer; Renée T Fortner; Margaret A Gates; A Heather Eliassen; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2013-03-21       Impact factor: 2.506

10.  Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.

Authors:  Thomas P Ahern; Timothy L Lash; Henrik T Sørensen; Lars Pedersen
Journal:  Breast Cancer Res       Date:  2008-12-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.